1Y Close · As of Aug 26, 2026
Prestige BioPharma Limited operates in the Professional Services sector.
Legal name: Prestige BioPharma Limited
In fiscal year 2025, Prestige BioPharma Limited (950210) reported revenue of 10 million KRW, up 1875.4% from 517,114 KRW a year earlier.
Operating profit was -48 million KRW and net income was 3 million KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 376.2 billion KRW, with a P/B of 1003.87.
These figures can be verified in the DART filing (receipt no. 20250923000316).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 10M | -48M | 3M |
| 2024 | 517,114 | -47M | -41M |
| 2023 | 122,410 | -53M | -2M |
| 2022 | — | -49M | -176M |
| 2021 | — | -16M | -7M |
Recent Filings
Largest Shareholder Change Report
Large Shareholding Report (General)
Officer/Major Shareholder Ownership Report
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-19 | Largest Shareholder Change Report |
| 2026-08-19 | Large Shareholding Report (General) |
| 2026-08-19 | Officer/Major Shareholder Ownership Report |
| 2026-08-14 | 매출액또는손익구조30%(대규모법인은15%)이상변경 |
| 2026-08-11 | Largest Shareholder Change Report |